| Today's Big NewsJun 27, 2023 |
| By Annalee Armstrong Fifty-eight pounds. That’s how much weight patients lost on average at the end of 48 weeks when taking Eli Lilly’s next-generation obesity treatment. Twenty four percent of their body weight. |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Nick Paul Taylor One of Sanofi’s priority assets has hit the primary endpoint in a phase 2b clinical trial. The candidate, which Sanofi snagged in its $1.1 billion Kymab buyout, improved outcomes in eczema patients, clearing the French drugmaker to push into phase 3 and boosting its prospects of targeting other diseases. |
By Annalee Armstrong A group of biotech leaders is calling on the industry to join the fight against gender-affirming care bans that are spreading across the U.S. |
Sponsored by Context Therapeutics Inc. In the ongoing search for new cancer treatments, companies including Context Therapeutics are developing potential therapies focused on the emerging novel oncology target Claudin 6. |
By Max Bayer Nkarta Therapeutics’ off-the-shelf natural killer cell therapy appears to be most effective against blood cancer when used with a specific lymphodepletion regimen. But that’s not what most patients have received so far. |
Sponsored by Sciensus Are you considering expanding your orphan drug in Europe? Discover key strategies to identify, engage and support rare disease patients, ensuring treatment adherence that makes a real difference. |
By Annalee Armstrong Women’s health biotech Freya Biosciences will advance an immunotherapy for a bacterial imbalance in the vagina into patients undergoing in vitro fertilization after early-stage results showed resolution of the condition. |
By James Waldron June has been something of a roller coaster month for Aldeyra Therapeutics. The immune-focused biotech has dived from a phase 3 win down to an FDA rejection and has now leveled out on some positive, if uninspiring, midstage data. |
By Gabrielle Masson It’s been a rocky few years for Avalo Therapeutics, and the ride doesn’t look like it will be getting easier any time soon. The biotech's lead asset failed to stem asthma events, missing the main goal of a phase 2 clinical trial. |
By Max Bayer Erytech's merger with Pherecydes has reached the finish line after a contentious battle with an activist investor. The proposed merger was greenlighted by Erytech's shareholders, denying Akkadian Partners' request to reject it. |
By Gabrielle Masson Investor Blackstone Life Sciences is paying Sutro Biopharma $140 million cash and throwing in another potential $250 million in biobucks in exchange for royalties on possible future sales of Vaxcyte’s products. |
By Nick Paul Taylor Xentria’s bid to find a new use for TNF inhibitors has landed it a $45 million upfront. Building on evidence that Remicade improves outcomes in a lung disease, Xentria has persuaded Meitheal Pharmaceuticals to pay the upfront and offer more than $600 million in potential future paydays for North American rights to its candidate. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson Fierce Biotech's M&A Tracker, your one-stop shop for dealmaking in the biopharma universe. |
By Andrea Park Just a couple of months after laying out a plan to shave off at least $100 million from its 2023 expenses, Illumina is beginning to make those cost-cutting moves. |
By Angus Liu Despite the controversy surrounding a relationship with departing director Alex Denner, Susan Langer has secured enough investor support to join Biogen’s board. |
By Kevin Dunleavy For the first time in a decade, compensation for chief executives at S&P 500 companies declined in 2022. But you won’t find any evidence of the slide in biopharma. In an industry often said to be immune to economic headwinds, its top execs were again well compensated, with most getting significant bumps in pay |
By Fraiser Kansteiner While Energy and Commerce Committee Democrats are supporting five bills that seeking to tackle drug and medical device supply chain hiccups in the U.S., committee Republicans have so far declined to take up the prospective legislation. |
By Ayla Ellison The Fierce 50 is a groundbreaking project that shines a spotlight on the true powerhouses driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about the momentum behind addressing health equity challenges. Also under discussion is how social drivers of health are finally being recognized by CMS. |
|
|---|
|
|
|
September 26-28, 2023 | Philadelphia, PA Hear how to drive greater sponsor-CRO-site collaboration and communication, and the latest on oversight approaches for external stakeholders. Save $400 on Registration with the Early Bird Rate! 
|
|
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
